touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part Two click here.
1. What were the aims and design of the CAPTURE study? (00:18-02:25)
2. What were the study findings in the infection cohort? (02:25-04:31)
3. What were the study findings in the vaccinated cohort? (04:31-07:18)
Disclosures: Scott Shepherd has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In COVID-19
Pamela Kearns: Leading SIOP Europe during the COVID-19 Pandemic
touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss her experience as President of SIOP Europe during the COVID-19 pandemic, and the biggest achievements of the European paediatric oncology community during that time. Questions How would you describe your experience as the SIOP Europe President (2019–21) and how the COVID-19 pandemic influenced […]
Morgan Rouprêt, ESOU22: What Have We Learned From the COVID-19 Pandemic?
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss what we have learned from the COVID-19 pandemic, how this has impacted the care of cancer patients and what we can do to move forward. Questions What was the impact of the COVID-19 pandemic on […]
Mark Lawler, European Cancer Summit 2021: Time To Act: COVID-19 & Cancer Campaign
We were delighted to catch up with Prof Mark Lawler to discuss the challenges that the COVID-19 pandemic has had on cancer care in Europe, and the key objectives and messages of the Time To Act: COVID-19 & Cancer campaign. Questions 1. What has been the impact of the COVID-19 pandemic on cancer screening and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!